Late Breaker Abstracts
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B
Valecha et al. Malar J (2016) 15:42 DOI 10.1186/s12936-016-1084-1 Malaria Journal RESEARCH Open Access Comparison of the safety and efficacy of fixed‑dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open‑label study Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B. H. Krishnamoorthy Rao2, Santanu K. Tripathi3, Nithya Gogtay4, Sanjay Kumar Kochar5, Nalli Babu Vijaya Kumar6, Girish Chandra Rajadhyaksha7, Jitendra D. Lakhani8, Bhagirath B. Solanki9, Rajinder K. Jalali10, Sudershan Arora10, Arjun Roy10, Nilanjan Saha10, Sunil S. Iyer10, Pradeep Sharma10 and Anupkumar R. Anvikar1* Abstract Background: Chloroquine has been the treatment of choice for acute vivax malaria for more than 60 years. Malaria caused by Plasmodium vivax has recently shown resistance to chloroquine in some places. This study compared the efficacy and safety of fixed dose combination (FDC) of arterolane maleate and piperaquine phosphate (PQP) with chloroquine in the treatment of uncomplicated vivax malaria. Methods: Patients aged 13–65 years with confirmed mono-infection of P. vivax along with fever or fever in the previ- ous 48 h were included. The 317 eligible patients were randomly assigned to receive FDC of arterolane maleate and PQP (n 159) or chloroquine (n 158) for 3 days. Primaquine was given as an anti-relapse measure on day 3 and continued= for 14 consecutive days.= Primary efficacy analysis included assessment of the proportion of aparasitaemic and afebrile patients at 72 h. Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnor- malities on electrocardiograph. Patients participated in the study for at least 42 days. -
Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges
Hindawi BioMed Research International Volume 2021, Article ID 5539544, 12 pages https://doi.org/10.1155/2021/5539544 Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges Wote Amelo 1,2,3 and Eyasu Makonnen 1,2 1Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia 2Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia 3Department of Pharmacology and Toxicology, School of Pharmacy, Jimma University, Jimma, Ethiopia Correspondence should be addressed to Wote Amelo; [email protected] Received 21 January 2021; Accepted 9 August 2021; Published 30 August 2021 Academic Editor: Jane Hanrahan Copyright © 2021 Wote Amelo and Eyasu Makonnen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since 2000, a good deal of progress has been made in malaria control. However, there is still an unacceptably high burden of the disease and numerous challenges limiting advancement towards its elimination and ultimate eradication. Among the challenges is the antimalarial drug resistance, which has been documented for almost all antimalarial drugs in current use. As a result, the malaria research community is working on the modification of existing treatments as well as the discovery and development of new drugs to counter the resistance challenges. To this effect, many products are in the pipeline and expected to be marketed soon. In addition to drug and vaccine development, mass drug administration (MDA) is under scientific scrutiny as an important strategy for effective utilization of the developed products. -
Update Tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for The
Update tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Am j trop med hyg. 2020. 2. Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy. Ahn SJ, Joung J, Lee BR. American journal of ophthalmology. 2020;209:35-44. http://dx.doi.org/10.1016/j.ajo.2019.09.008. Epub 2019 Sep 14. 3. COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. J clin epidemiol. 2020. 4. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. Bauman JL, Tisdale JE. Pharmacotherapy. 2020. 5. Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials. Chang R, Sun W-Z. medRxiv. 2020:2020.04.18.20071167. 6. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Int J Antimicrob Agents. 2020:105932-. 7. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Cui C, Zhang M, Yao X, Tu S, Hou Z, Jie En VS, et al. Acta Pharmaceutica Sinica B. 2020. 8. Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia? Could It Be A Prophylactic Drug? Deniz O. -
Fixed Dose Combinations Approved by Dcg (I) Since 1961 Till February, 2013
FIXED DOSE COMBINATIONS APPROVED BY DCG (I) SINCE 1961 TILL FEBRUARY, 2013 # Name of Drug Indication Date of approval 1. Cyanocobalamine + Zinc tannic acid complex Jan-61 2. Cobalt glutamate + Copper Glycinate Aug-61 3. Fibrinolysin + Desoxyribonuclease Feb-62 4. Tablets of Norethisterone acetate + Ethinyl Nov-62 oestradiol 5. Tablets of Norethynodrel and Ethinyl Estradiol 3-methyl ether Dec-62 6. Broxyquinoline + Brobenzoxalidine May-63 7. Testosterone decanoate + Isocaproate Jan-64 8. Combination of L Oxethazaine + Aluminium hydroxide + Magnesium Hydroxide Jun-66 9. Amylobarbitone + Trifluperazine Dihydrochloride Capsule Feb-67 10. Lynestronol 2.5mg + Mestranol 0.075mg Tablet Apr-67 11. Northynodrel 2.5mg + Mestranol 0.1mg Jun-67 12. Norethisterone 2mg and Mestranol 0.1mg May-67 13. Mestranol 4mg + Ethinyloestradial 0.05mg May-67 Tablet 14. Norethisterane acetate + ethinyl estradiol May-67 15. Aluminium sodium silicate + Magnesium hydroxide + Methypolysiloxane Tablet Jun-67 16. Ammoidin + Amidine Jul-67 17. Fluocortolene + Flucortolene Caproate Jul-68 18. Norgestrel + Ethinyloestradiol Tablet Aug-68 19. Folic Acid 0.5mg + Ferrous Sulphate 150mg Jan-69 Capsule 20. Tetracycline HCl 250mg + Broxyquinoline 200mg + Brobenzoxadine 40mg Jan-69 21. Methyldopa 250mg + HCTZ 15mg Tablet Feb-69 22. dl Norgestrel + 17 alpha hydroxy progesterone caproate + Norethisterone acetate + 17 alpha Jan-69 acetoxy progesterone 23. Diphenoxylate HCl 2.5mg + Atropine Sulphate 0.025mg tablet Jul-69 24. Vitamin A,D & E Jul-69 25. Lutin 0.1gm + Vit 0.1gm + Vit K1 2.5mg + Dicalcium Phosphate 0.1gm + Carlozochrome Jul-69 Salicylate 1mg tablet 26. Vit K 1 5mg + Calcium Lactolionate 100 m g+ Carlozocrome Salicylate 2.5mg + Phenol 0.5% Jul-69 + Lignocaine Hcl 1% injection 27. -
PHARMACOLOGY of NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S
REVIEW ARTICLE PHARMACOLOGY OF NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S. Kondaveti2 HOW TO CITE THIS ARTICLE: Bhuvaneshwari, Souri S. Kondaveti. ‖Pharmacology of Newer Antimalarial Drugs: Review Article‖. Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 4, January 26, 2015; Page: 431-439. ABSTRACT: Malaria is currently is a major health problem, which has been attributed to wide spread resistance of the anopheles mosquito to the economical insecticides and increasing prevalence of drug resistance to plasmodium falciparum. Newer drugs are needed as there is a continual threat of emergence of resistance to both artemisins and the partner medicines. Newer artemisinin compounds like Artemisone, Artemisnic acid, Sodium artelinate, Arteflene, Synthetic peroxides like arterolane which is a synthetic trioxolane cognener of artemisins, OZ439 a second generation synthetic peroxide are under studies. Newer artemisinin combinations include Arterolane(150mg) + Piperaquine (750mg), DHA (120mg) + Piperaquine(960mg) (1:8), Artesunate + Pyronardine (1:3), Artesunate + Chlorproguanil + Dapsone, Artemisinin (125mg) + Napthoquine (50mg) single dose and Artesunate + Ferroquine.Newer drugs under development including Transmission blocking compounds like Bulaquine, Etaquine, Tafenoquine, which are primaquine congeners, Spiroindalone, Trioxaquine DU 1302, Epoxamicin, Quinolone 3 Di aryl ether. Newer drugs targeting blood & liver stages which include Ferroquine, Albitiazolium – (SAR – 97276). Older drugs with new use in malaria like beta blockers, calcium channel blockers, protease inhibitors, Dihydroorotate dehydrogenase inhibitors, methotrexate, Sevuparin sodium, auranofin, are under preclinical studies which also target blood and liver stages. Antibiotics like Fosmidomycin and Azithromycin in combination with Artesunate, Chloroquine, Clindamycin are also undergoing trials for treatment of malaria. Vaccines - RTS, S– the most effective malarial vaccine tested to date. -
Drug Targets of the Heartworm, Dirofilaria Immitis
Drug Targets of the Heartworm, Dirofilaria immitis Inauguraldissertation zur Erlangung des Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Christelle Godel aus La Sagne (NE) und Domdidier (FR) Schweiz Avenches, 2012 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Jürg Utzinger Prof. Dr. Pascal Mäser P.D. Dr. Ronald Kaminsky Prof. Dr. Georg von Samson-Himmelstjerna Basel, den 26th of June 2012 Prof. Dr. M. Spiess Dekan To my husband and my daughter With all my love. Table of Content P a g e | 2 Table of Content Table of Content P a g e | 3 Acknowledgements ............................................................................................................... 5 Summary ............................................................................................................................... 8 Introduction ..........................................................................................................................11 Dirofilaria immitis ..............................................................................................................12 Phylogeny and morphology ...........................................................................................12 Repartition and ecology .................................................................................................14 Life cycle .......................................................................................................................16 -
List of Participants
List of Participants 966 Part. 10.1 (Rev.) PARTIES/PARTES ALGERIA/ARGELIA/ALGERIE AUSTRIA/AUTRICHE BELHIMEUR, Merzak (*) DICK, Gerald BOUCHOUCHA, Rabah Ottakringerstr. 114-116 Embassy of the Democratic People's Republic of Algeria A-1160 WIEN 8, Pascoe Avenue LIEBEL, Günter Belgravia Federal Ministry of the Environment, Youth and Family HARARE Abteilung II/5 Zimbabwe Stubenbastei 5 ARGENTINA/ARGENTINE A-1010 WIEN DE LA ZERDA, Luis Héctor MUELLER, Hugo Av. El Congreso esq. El Inti - Bq The Federal States of Austria Parque Industrial - ex Casino Gral Bezirkshauptmannschaft Feldkirch San Martin Schlossgraben 1 PALPALA A-6800 FELDKIRCH Jujuy RICK, Oskar IRBIBARREN, Federico Jesus Austrian Federal Economic Chamber RAMADORI, Edgardo Daniel Wiedner Hauptstrasse 63 Secretaría de Recursos Naturales y Desarrollo Sustentable A-1045 WIEN San Martín 459 SCHOBER, Peter Josef (*) 1004 BUENOS AIRES Ministry for Economic Affairs LICHTSCHEIN, Victoria (*) Landstrasser Hauptstrasse 55-57 Directora de Fauna y Flora Silvestre A-1031 VIENNA Autoridad Administrativa CITES BAHAMAS San Martín 459 - 3q Piso 1004 BUENOS AIRES DELEVEAUX, Edison ISAACS, Maurice (*) MASCIAS URQUIZA, Carlos Department of Agriculture 29 Belfast Rd P.O. Box No. 3028 HARARE NASSAU Zimbabwe BANGLADESH AUSTRALIA/AUSTRALIE CHOWDHURY, H.A. FULLER, Colin High Commission of Bangladesh LEE, Robert N 4 Downie Avenue Parks and Wildlife Commission of the Northern Territory q HARARE P.O. Box 496 Zimbabwe PALMERSTON NT 0831 BELARUS/BELARUS HOLDEN, Jane TRAFFIC Oceania PODOLYAKO, Vasily (*) GPO Box 528 ZHARSKAYA, Olga SYDNEY, NSW 2001 Ministry of Natural Resources and Environmental Protection Kollectornaya Str. 10 JENKINS, Robert MINSK 220048 KAY, David (*) MOORE, Robert BELGIUM/BELGICA/BELGIQUE Environment Australia DE MEULENAER, Tom GPO Box 636 c/o TRAFFIC Europe CANBERRA ACT 2601 608, chaussée de Waterloo KRUX, Robyn B-1060 BRUXELLES NSW National Parks and Wildlife Service EVRARD, Georges (*) P.O. -
Synthetic Ozonide Drug Candidate OZ439 Offers New Hope for a Single-Dose Cure of Uncomplicated Malaria
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria Susan A. Charmana, Sarah Arbe-Barnesb, Ian C. Bathurstc, Reto Brund,e, Michael Campbella, William N. Charmana, Francis C. K. Chiua, Jacques Cholletd,e, J. Carl Craftc, Darren J. Creeka, Yuxiang Dongf, Hugues Matileg, Melanie Maurerd,e, Julia Morizzia, Tien Nguyena, Petros Papastogiannidisd,e, Christian Scheurerd,e, David M. Shackleforda, Kamaraj Sriraghavanf, Lukas Stingelina, Yuanqing Tangf, Heinrich Urwylerh, Xiaofang Wangf, Karen L. Whitea, Sergio Wittlind,e, Lin Zhouf, and Jonathan L. Vennerstromf,1 aCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; bFulcrum Pharma Developments Ltd., Hemel Hempstead, Hertfordshire HP1 1JY, United Kingdom; cMedicines for Malaria Venture, CH-1215 Geneva, Switzerland; dSwiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland; eUniversity of Basel, CH-4051 Basel, Switzerland; fCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6025; gF. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland; and hBasilea Pharmaceutica Ltd., CH-4058 Basel, Switzerland Edited by Thomas E. Wellems, National Institutes of Health, Bethesda, MD, and approved January 11, 2011 (received for review October 21, 2010) Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate Thai-Cambodian border, and more recently, increased parasite designed to provide a single-dose oral cure in humans. OZ439 has clearance times with artesunate (AS) monotherapy, have raised successfully completed Phase I clinical trials, where it was shown to significant concerns that resistance to these agents may be be safe at doses up to 1,600 mg and is currently undergoing Phase emerging (2, 3). -
New Targets in Malaria Parasite Chemotherapy: a Review
trol & E on lim C in ia a r t a i l o a n M Malaria Control & Nigussie D, Malaria Contr Elimination 2015, S1:1 DOI: 10.4172/2470-6965/1000S1-007 ISSN: 2470-6965 Elimination Review Article Open Access New Targets in Malaria Parasite Chemotherapy: A Review Dereje Nigussie1*, Takele Beyene2, Naseer Ali Shah3 and Sileshi Belew4 1Ethiopian Public Health Institute, Addis Ababa, Ethiopia, Tel: 011 2 13 34 99; Fax: +00251 1 2754744 / 757722; Email: [email protected] 2Addis Ababa University, College of Agriculture and Veterinary Medicine, Department of Biomedical Science, Debrezeit, Ethiopia 3COMSATS Institute of Information Technology, Department of Biosciences, Islamabad, Pakistan 4Jimma University College of agriculture and Veterinary medicine, P.O. Box 307, Jimma, Ethiopia *Corresponding author: Dereje Nigussie, Vaccines and diagnostic Production directorate, Ethiopian Public Health Institute, P.O. Box 1242, Addis Ababa, Ethiopia, Tel: +251911660850; E-mail: [email protected] Rec date: Oct 31, 2015, Acc date: Nov 24, 2015, Pub date: Nov 30, 2015 Copyright: © 2015 Nigussie D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Malaria is a global health problem that causes significant mortality and morbidity annually and a serious problem to drug therapy and discovery as current anti-malarial therapeutics become increasingly ineffective. The need for new therapy for malaria is mandatory because of the emergence of resistance to most of the anti-malarial drugs. There are different approaches and targets proposed by researchers and scientist based on experimental data. -
A Variant Pfcrt Isoform Can Contribute to Plasmodium Falciparum Resistance to the First-Line Partner Drug Piperaquine" (2017)
Old Dominion University ODU Digital Commons Biological Sciences Faculty Publications Biological Sciences 5-2017 A Variant PfCRT Isoform Can Contribute to Plasmodium Falciparum Resistance to the First- Line Partner Drug Piperaquine Satish K. Dhingra Devasha Redhi Jill M. Combrinck Tomas Yeo John Okombo See next page for additional authors Follow this and additional works at: https://digitalcommons.odu.edu/biology_fac_pubs Part of the Biology Commons, Parasitic Diseases Commons, and the Pharmacology Commons Repository Citation Dhingra, Satish K.; Redhi, Devasha; Combrinck, Jill M.; Yeo, Tomas; Okombo, John; Henrich, Philipp P.; Cowell, Annie N.; Gupta, Purva; Stegman, Matthew L.; Hoke, Jonathan M.; Cooper, Roland A.; Winzeler, Elizabeth; Mok, Sachel; Egan, Timothy J.; and Fidock, David A., "A Variant PfCRT Isoform Can Contribute to Plasmodium Falciparum Resistance to the First-Line Partner Drug Piperaquine" (2017). Biological Sciences Faculty Publications. 211. https://digitalcommons.odu.edu/biology_fac_pubs/211 Original Publication Citation Dhingra, S. K., Redhi, D., Combrinck, J. M., Yeo, T., Okombo, J., Henrich, P. P., . Fidock, D. A. (2017). A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. MBio, 8(3). e00303-17 doi:10.1128/ mBio.00303-17 Authors Satish K. Dhingra, Devasha Redhi, Jill M. Combrinck, Tomas Yeo, John Okombo, Philipp P. Henrich, Annie N. Cowell, Purva Gupta, Matthew L. Stegman, Jonathan M. Hoke, Roland A. Cooper, Elizabeth Winzeler, Sachel Mok, Timothy J. Egan, and David A. Fidock This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/biology_fac_pubs/211 Downloaded from RESEARCH ARTICLE crossm mbio.asm.org A Variant PfCRT Isoform Can Contribute on May 16, 2017 - Published by to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine Satish K. -
WTA Tour Statistical Abstract 2000
WTA Tour Statistical Abstract 2000 Robert B. Waltz ©2000 by Robert B. Waltz Reproduction and/or distribution for profit prohibited Contents 2000 In Review: Top Players 5 Wins Over Top Players 57 Tournament Wins by Surface 98 The Final Top Twenty-Five 5 Matches Played/Won against the (Final) Assorted Statistics 99 The Beginning Top Twenty-Five 6 Top Twenty 57 Summary of Changes 2000 6 Won/Lost Versus the Top Players (Based on The Busiest Players on the Tour 99 Rankings at the Time of the Match) 58 Total Matches Played by Top Players 99 All the Players in the Top Ten in 2000 7 Total Events Played by the Top 150 100 The Complete Top Ten Based on WTA Won/Lost Versus the Top Players (Based on (Best 18) Statistics 7 Final Rankings) 59 The Biggest Tournaments 101 The Complete Top Ten under the 1996 Statistics/Rankings Based on Head-to- Tournament Strength Based on the Four Top Ranking System 7 Head Numbers 60 Players Present 102 Ranking Fluctuation 8 Total Wins over Top Ten Players 60 The Top Tournaments Based on Top Players Top Players Sorted by Median Ranking 9 Winning Percentage against Top Ten Present — Method 1 103 Players 60 The Top Tournaments Based on Top Players Tournament Results 10 Present — Method 2 104 Tournaments Played/Summary of Results How They Earned Their Points 61 Strongest Tournaments Won 105 for Top Players 10 Fraction of Points Earned in Slams 61 Strongest Tournament Performances The Rankings (Top 192 — As of November Quality Versus Round Points 62 106 20, 2000. -
Dondorp, Background on Malaria and Combination Anti-Malarial Drug Therapy
Background on Malaria and Combination Anti-Malarial Drug Therapy FDA Workshop: Clinical Trial Design Considerations for Malaria Drug Development 30 June 2016 Prof. Arjen M. Dondorp Mahidol Oxford Tropical Medicine Research Unit The 5 human Plasmodium species P. falciparum P. vivax Anopheles P. knowlesi P. malariae P. ovale H. sapiens M. fascicularis/ nemestrina Life-cycle of Plasmodium White et al; Lancet 2014 Artemisinins: the best drugs for reducing malaria mortality Log-rank p=0.0002 SEAQUAMAT Asia 4 countries N=1,461 Δ=35% (202 children) AQUAMAT Artesunate Africa 9 countries Δ=23% N=5,425 Quinine (all children) Dondorp et al. Lancet 2010; SEAQUAMAT investigators group. Lancet 2005 Broader stage specificity explains superiority of artemisins rapid action, broad stage specificity, safe, easy administration White; Science 2009 Differences in potency TOTAL PARASITES Artesunate best drug to treat severe malaria 1012 Fastest for the artemisinins 1010 Detection limit 108 106 104 104 103 102 10 Reduction/ 48h-cycle 102 MQ, PQP, 0 Artesunate Malarone Doxycycline 0 1 2 3 4 WEEKS = artemisinin resistance Courtesy NJ White Differences in pharmacokinetics 100% M C P Plasma concentration (%) concentration Plasma A Q 0% 0 1 2 3 4 Time after start treatment (weeks) Courtesy NJ White Artemisinin resistance: a prelude to ACT failure 1. W-Cambodia 2007-2008 2012-2013 2012-2014 Slow clearance DHA-piperquine efficacy DHA-piperquine 42-day failures Source CNM Cambodia/ WHO Map by Richard Maude Dondorp et al. Amaratunga et al. N Eng J Med 2009 Lancet Infect Dis 2016 The molecular marker for artemisinin resistance: Kelch 13 K13 mutations in the “propeller region” strongly associates with the slow clearing phenotype multiple SNPs in the propeller region, but: only 1 mutation per clone seems permitted Ariey et al.